Mundipharma network of independently associated companies recently announced that it has appointed Marc Princen as the Global Chief Executive Officer, effective June 1, 2020. In his new role, Princen will be responsible for all Mundipharma strategic and operational matters globally, focusing on seamless execution of the 2020-2023 Business Plan. Speaking of the appointment, Jacques Theurillat,…
Mundipharma has announced partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong. The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab). Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung…